Icure Pharmaceutical Incorporation (KOSDAQ:175250)
South Korea · Delayed Price · Currency is KRW 2,170.00
+231.00 (11.91%)
At close: Aug 5, 2025
KOSDAQ:175250 Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -33,600 | 1,198 | -31,272 | -41,766 | -38,167 |
Depreciation & Amortization | 6,779 | 8,786 | 9,043 | 8,216 | 7,778 |
Loss (Gain) From Sale of Assets | 93.96 | -31,657 | -51.52 | 70.11 | -490.69 |
Asset Writedown & Restructuring Costs | 12,840 | 8,791 | - | 1,292 | 3,040 |
Loss (Gain) From Sale of Investments | 284.92 | 1,875 | 552.81 | 2,027 | 159.8 |
Loss (Gain) on Equity Investments | -2,377 | -417.96 | -1,213 | 2,259 | 3,228 |
Stock-Based Compensation | 37.35 | -11.64 | 81.65 | 296.37 | 575.49 |
Provision & Write-off of Bad Debts | 1,794 | 861.85 | 881.12 | 1,088 | 1,742 |
Other Operating Activities | 7,191 | 1,951 | 7,673 | 9,779 | 3,046 |
Change in Accounts Receivable | -6,143 | -3,877 | -418.55 | 658.13 | 6,273 |
Change in Inventory | 2,306 | -170.24 | -2,473 | 6,431 | -4,888 |
Change in Accounts Payable | 4,000 | -607.83 | 1,831 | 146.21 | -6,911 |
Change in Other Net Operating Assets | 4,109 | -3,774 | 1,847 | -1,780 | -1,615 |
Operating Cash Flow | -2,685 | -17,054 | -13,519 | -11,282 | -26,228 |
Capital Expenditures | -5,110 | -2,023 | -2,225 | -4,197 | -5,701 |
Sale of Property, Plant & Equipment | 35.91 | 68,028 | 284.52 | 187.72 | 1,782 |
Cash Acquisitions | - | -246.43 | - | -46.71 | - |
Divestitures | 9,781 | - | 2.5 | - | 0.47 |
Sale (Purchase) of Intangibles | -355.38 | -486.8 | -401.25 | -1,767 | -1,006 |
Investment in Securities | -2,779 | -3,254 | 2,931 | 11,739 | -13,186 |
Other Investing Activities | -820.77 | 1,290 | -294.53 | -351.52 | 159.86 |
Investing Cash Flow | 1,165 | 61,985 | 3,047 | 2,232 | -20,318 |
Short-Term Debt Issued | 9,280 | 3,700 | 6,610 | 5,000 | 2,000 |
Long-Term Debt Issued | - | 19,849 | 14,842 | 4,000 | 53,773 |
Total Debt Issued | 9,280 | 23,549 | 21,452 | 9,000 | 55,773 |
Short-Term Debt Repaid | -100 | -34,410 | -500 | -417.63 | - |
Long-Term Debt Repaid | -16,575 | -23,388 | -54,689 | -448.05 | -2,382 |
Total Debt Repaid | -16,675 | -57,798 | -55,189 | -865.68 | -2,382 |
Net Debt Issued (Repaid) | -7,395 | -34,249 | -33,738 | 8,134 | 53,391 |
Issuance of Common Stock | - | - | - | 33,724 | - |
Repurchase of Common Stock | - | - | - | -547.51 | - |
Other Financing Activities | - | 170.68 | -26.13 | 3 | 1,957 |
Financing Cash Flow | -7,395 | -34,078 | -33,764 | 41,813 | 58,398 |
Foreign Exchange Rate Adjustments | - | 0 | -1.67 | 0 | 41.97 |
Miscellaneous Cash Flow Adjustments | - | - | -0 | - | -0 |
Net Cash Flow | -8,914 | 10,853 | -44,237 | 32,763 | 11,893 |
Free Cash Flow | -7,795 | -19,077 | -15,744 | -15,479 | -31,929 |
Free Cash Flow Margin | -9.35% | -37.62% | -27.72% | -26.07% | -49.67% |
Free Cash Flow Per Share | -208.09 | -509.73 | -419.20 | -664.50 | -1474.52 |
Cash Interest Paid | 2,200 | 3,492 | 3,619 | 1,517 | 1,177 |
Cash Income Tax Paid | 13.89 | -134.21 | -92.53 | 176.13 | 298.18 |
Levered Free Cash Flow | -6,314 | -4,420 | -18,557 | 8,609 | -28,205 |
Unlevered Free Cash Flow | -4,177 | -1,841 | -15,001 | 13,158 | -24,817 |
Change in Working Capital | 4,271 | -8,429 | 785.73 | 5,456 | -7,141 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.